AdvaMed Supports United States-Mexico-Canada Agreement Renewal 

WASHINGTON—AdvaMed, the Medtech Association, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker, AdvaMed president and CEO, made the following comment on the renewal. 

“The U.S. medtech sector is a cornerstone of American manufacturing, research and development, and global health care delivery. Trade agreements such as the United States-Mexico-Canada Agreement have strengthened U.S. leadership in medtech innovation and production while ensuring our innovators can maintain the supply chains necessary to serve American patients and lead the world in medtech exports. We appreciate President Trump’s vision in negotiating the agreement and his ongoing interest in ensuring U.S.-led industries such as medtech continue providing good-paying jobs for Americans and lifesaving technologies for patients here and everywhere.  

“AdvaMed also appreciates Chairman Crapo and Ranking Member Wyden and the U.S. Senate Committee on Finance for their hearing covering USMCA’s many benefits and the ways its implementation can continue to be improved for regulatory convergence and other sound trade practices. Another important note about USMCA is the predictability and stability it provides. What I hear most from medtech companies on trade policy is about the need for predictability and certainty on trade and tariff policy to make the investment decisions necessary to create jobs and maintain their supply chains. Because USMCA has been in place for several years now, companies have been able to plan accordingly, to the benefit of our country. 

“We look forward to continuing to work with the Administration and Congress on strong, predictable, certain trade policy serving U.S. patients, hospitals, and communities.”

###